Company needs to up the Marketing Ante on their peer reviewed results.. Genentech spent ~3Billion on AVASTIN [one of the use cases was for Wet AMD]. They also got sued B/C AVASTIN performed horribly in breast cancer for women.
All of the above was W/O the ability nor benefit of gene-Editing nor feedback from reading back edited DNA via NextGEN Seq.
There are companies out there that will THROW $100's of Millions, now that CRISPR is FDA approved. No more MoUs & LOIs etc...ask for Investment & Committed POs. Have a Good Weekend.
I've said it numerous times, ABBIE is 8-10 year old tech. It's gone through a few companies before and no one went with it. There's a reason it landed with a OTC Pink Sheet company like SHMN.
News 
Market Data 
Discover 
